[go: up one dir, main page]

NO20081973L - PDE inhibitorer og kombinasjoner derav i behandlingen av urologiske lidelser - Google Patents

PDE inhibitorer og kombinasjoner derav i behandlingen av urologiske lidelser

Info

Publication number
NO20081973L
NO20081973L NO20081973A NO20081973A NO20081973L NO 20081973 L NO20081973 L NO 20081973L NO 20081973 A NO20081973 A NO 20081973A NO 20081973 A NO20081973 A NO 20081973A NO 20081973 L NO20081973 L NO 20081973L
Authority
NO
Norway
Prior art keywords
treatment
pde
urological disorders
combinations
inhibitors
Prior art date
Application number
NO20081973A
Other languages
English (en)
Norwegian (no)
Inventor
Ernst Ulbrich
Peter Sandner
Hanna Tinel
Joachim Hutter
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37831473&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20081973(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of NO20081973L publication Critical patent/NO20081973L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
NO20081973A 2005-09-29 2008-04-24 PDE inhibitorer og kombinasjoner derav i behandlingen av urologiske lidelser NO20081973L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05021261 2005-09-29
EP06007776 2006-04-13
PCT/EP2006/009040 WO2007039075A2 (fr) 2005-09-29 2006-09-16 Inhibiteurs pde et combinaisons de ceux-ci pour traiter des troubles urinaires

Publications (1)

Publication Number Publication Date
NO20081973L true NO20081973L (no) 2008-06-20

Family

ID=37831473

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081973A NO20081973L (no) 2005-09-29 2008-04-24 PDE inhibitorer og kombinasjoner derav i behandlingen av urologiske lidelser

Country Status (23)

Country Link
US (1) US20090186896A1 (fr)
EP (1) EP1931797A2 (fr)
JP (1) JP2009509984A (fr)
KR (1) KR20080056250A (fr)
AR (1) AR057867A1 (fr)
AU (1) AU2006299232A1 (fr)
BR (1) BRPI0616633A2 (fr)
CA (1) CA2623657A1 (fr)
CR (1) CR9840A (fr)
DO (1) DOP2006000207A (fr)
EC (1) ECSP088311A (fr)
GT (1) GT200600442A (fr)
IL (1) IL190201A0 (fr)
MA (1) MA29880B1 (fr)
NO (1) NO20081973L (fr)
PE (1) PE20070587A1 (fr)
RU (1) RU2435588C2 (fr)
SG (1) SG166106A1 (fr)
SV (1) SV2009002851A (fr)
TN (1) TNSN08147A1 (fr)
TW (1) TW200804603A (fr)
UY (1) UY29816A1 (fr)
WO (1) WO2007039075A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113243A2 (fr) * 2006-03-31 2007-10-11 Investigación Y Clínica Andrológicas S.L. Utilisation des inhibiteurs de la pde 5 pour le traitement de la vessie hyperactive
MX2009011387A (es) * 2007-05-12 2009-11-09 Bayer Schering Pharma Ag Estimulantes de la gcs, activadores de la gcs y combinaciones para el tratamiento de trastornos urologicos.
US20110171195A1 (en) * 2007-06-15 2011-07-14 Duke University Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp
AU2008307905A1 (en) * 2007-10-02 2009-04-09 Dond-A Pharm.Co., Ltd. Composition and method for treatment or prevention of benign prostatic hyperplasia and lower urinary tract symptoms
CN103351390A (zh) * 2007-11-21 2013-10-16 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4 抑制剂
EP2156847A1 (fr) * 2008-08-19 2010-02-24 Sanofi-Aventis Nouvelle combinaison d'ingrédients actifs contenant un alpha1-antagoniste et un inhibiteur de PDE 4
EP2266567A1 (fr) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Composition pharmaceutique comprenant de Cetrorelix e d'inhibiteurs de PDE V pour le traitement des étas dépendants de l'hormone sexuel
EP2266568A1 (fr) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Composition pharmaceutique comprenant d'antagonistes de LHRH et d'inhibiteurs de PDE V pour le traitement des états dépendants de l'hormone sexuel
JP2011184433A (ja) * 2010-02-09 2011-09-22 Daiichi Sankyo Healthcare Co Ltd バルデナフィル含有内服液剤組成物
JO3264B1 (ar) 2013-03-13 2018-09-16 Lilly Co Eli مركبات ازيتيدينيل أوكسي فينيل بيروليدين
KR102239291B1 (ko) * 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
EP3082428A4 (fr) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Formulations en poudre d'inhibiteur pde5 et procédés y associés
US20160311826A1 (en) * 2013-12-11 2016-10-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
KR20230116098A (ko) 2014-08-12 2023-08-03 주식회사 메지온 유데나필 조성물을 이용하여 폰탄 환자에서 심근 성능을개선시키는 방법
WO2016033776A1 (fr) 2014-09-04 2016-03-10 Eli Lilly And Company (2s)-3-[(3s,4s)-3-[(1r)-1-hydroxyéthyl]-4-(4-méthoxy-3-{[1-(5-méthylpyridin-2-yl)azétidin-3-yl]oxy}phényl)-3-méthylpyrrolidin-1-yl]-3-oxopropane-1,2-diol cristallin
AR101696A1 (es) 2014-09-12 2017-01-04 Lilly Co Eli Compuestos de azetidiniloxifenilpirrolidina
UA128502C2 (uk) 2018-03-23 2024-07-31 Лаборатуар Мажор Застосування композиції у негормональному способі контрацепції для суб’єкта чоловічої статі
EP3914701B1 (fr) * 2019-01-23 2025-12-03 Path Therapeutics Inc. Méthodes de traitement de l'épilepsie par inhibition de la phosphodiestérase 4 b (pde4)
US12274680B2 (en) 2022-09-13 2025-04-15 II George William Creasy Treatment of benign prostatic hypertrophy with capsinoids
US20250221990A1 (en) * 2023-08-21 2025-07-10 Cmpd Licensing, Llc Topical administration to the oral cavity

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2705715A (en) * 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
CH367510A (de) * 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
GB1051734A (fr) * 1963-01-16
GB1042471A (en) * 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
US3169129A (en) * 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) * 1966-03-02 1969-04-29 Table iii
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) * 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) * 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
DE3166627D1 (en) * 1980-12-12 1984-11-15 Thomae Gmbh Dr K Pyrimidones, their preparation and medicines containing them
US4431440A (en) * 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
US4666908A (en) * 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (fr) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Derives de purinone utilises comme bronchodilatateurs,vasodilatateurs et agents anti-allergiques
US5254571A (en) * 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
DE68908786T2 (de) * 1988-06-16 1994-03-17 Smith Kline French Lab Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) * 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
EP0524180B1 (fr) * 1990-04-11 1995-04-26 The Upjohn Company Masquage du gout de l'ibuprofene
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
DE19540642A1 (de) * 1995-11-01 1997-05-07 Stief Christian Georg Priv Doz Verwendung von Inhibitoren der Phosphodiesterase bei der Behandlung von Prostataerkrankungen
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
CA2309332C (fr) * 1997-11-12 2002-12-03 Bayer Aktiengesellschaft Imidazotriazinones a substitution 2-phenyle utilisees comme inhibiteurs des phosphodiesterases
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
AU7360700A (en) * 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
CA2323008C (fr) * 1999-10-11 2005-07-12 Pfizer Inc. Composes pharmaceutiques actifs
US6803365B2 (en) * 1999-12-24 2004-10-12 Bayer Aktlengesellschaft Imidazo[1,3,5]triazinones and the use thereof
EP1365806A2 (fr) * 2000-04-19 2003-12-03 Johns Hopkins University Utilzation d'activators de no pour le traitement et la prevention des troubles gastrointestinaux
ATE266407T1 (de) * 2000-10-30 2004-05-15 Lupin Ltd Schnell zerfallende cefuroxim axetil enthaltende arzneizusammensetzung mit verzögerter wirkstoffabgabe
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
EP1366760B1 (fr) * 2001-02-15 2010-06-30 Mitsubishi Tanabe Pharma Corporation Comprimes a dissolution rapide dans la cavite buccale
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
WO2002089808A1 (fr) * 2001-05-09 2002-11-14 Bayer Healthcare Ag Nouvelle utilisation d'imidazotriazinones substituees 2-phenyl
RU2192864C1 (ru) * 2001-07-23 2002-11-20 Гусева Наталья Борисовна Способ лечения нейрогенной дисфункции мочевого пузыря
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
US7118765B2 (en) * 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
ES2378374T3 (es) * 2003-11-20 2012-04-11 Astellas Pharma Inc. Inhibidores de la PDE 4 para el tratamiento de la cistitis intersticial
NZ550809A (en) * 2004-04-27 2010-07-30 Medicinova Inc Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
US20070004745A1 (en) * 2005-03-25 2007-01-04 Schering-Plough Corporation Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors
MX2008000087A (es) * 2005-06-23 2008-03-18 Schering Corp Formulaciones orales rapidamente absorbentes de inhibidores de la fosfodiesterasa 5.
MX2009011387A (es) * 2007-05-12 2009-11-09 Bayer Schering Pharma Ag Estimulantes de la gcs, activadores de la gcs y combinaciones para el tratamiento de trastornos urologicos.

Also Published As

Publication number Publication date
UY29816A1 (es) 2007-04-30
BRPI0616633A2 (pt) 2011-06-28
SV2009002851A (es) 2009-01-14
US20090186896A1 (en) 2009-07-23
PE20070587A1 (es) 2007-08-17
MA29880B1 (fr) 2008-10-03
TNSN08147A1 (en) 2009-07-14
ECSP088311A (es) 2008-06-30
EP1931797A2 (fr) 2008-06-18
KR20080056250A (ko) 2008-06-20
GT200600442A (es) 2007-05-15
JP2009509984A (ja) 2009-03-12
IL190201A0 (en) 2008-11-03
TW200804603A (en) 2008-01-16
RU2435588C2 (ru) 2011-12-10
SG166106A1 (en) 2010-11-29
CA2623657A1 (fr) 2007-04-12
WO2007039075A3 (fr) 2007-06-21
DOP2006000207A (es) 2007-07-15
WO2007039075A2 (fr) 2007-04-12
RU2008116547A (ru) 2009-11-10
CR9840A (es) 2008-10-31
AU2006299232A1 (en) 2007-04-12
AR057867A1 (es) 2007-12-26

Similar Documents

Publication Publication Date Title
NO20081973L (no) PDE inhibitorer og kombinasjoner derav i behandlingen av urologiske lidelser
WO2006044860A3 (fr) Composes de thiadiazole et leurs procedes d'utilisation
WO2008019139A3 (fr) Inhibiteurs de la pyruvate kinase et procédés de traitement de maladie
NO20060978L (no) Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
WO2008013589A3 (fr) Traitement de tumeurs exprimant ras
TW200724154A (en) Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
WO2008029276A3 (fr) Compositions et procédés de traitement d'une maladie ophtalmique
EP2319925A3 (fr) Utilisations thérapeutiques d'inhibiteurs du RTP801
WO2005075665A3 (fr) Agents diagnostiques et therapeutiques pour des maladies associees a la kallikreine plasmatique (klkb1)
NO20071926L (no) Anvendelse av en mTOR-inhibitor i behandling av uterint leioyom.
HRP20090498T1 (hr) Kombinacija r,r-glikopirolata, roliprama i budesonida za liječenje upalnih oboljenja
MY164900A (en) Use of an alpha-adrenoceptor antagonist in combination with a muscarinic antagonist in the manufacture of a medicament for treating the lower urinary tract symptoms associated with benign prostatic hyperplasia
MX2009011387A (es) Estimulantes de la gcs, activadores de la gcs y combinaciones para el tratamiento de trastornos urologicos.
WO2005074598A3 (fr) Composes precurseurs de nitroxyle et methodes d'utilisation
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
WO2005074375A3 (fr) Inhibiteurs de l'heparanase et utilisations
EP2196201A3 (fr) Combinaison d'un ligand alpha-2-delta avec un inhibiteur de pdev ou avec un antagoniste muscarinique pour traiter les symptomes des voies urinaires inferieures
BR0308634A (pt) Uso de um adenovìrus, e, composição
WO2006102232A3 (fr) Schemas posologiques pour le trans-clomiphene
PL1732534T3 (pl) Zastosowanie pochodnych amidowych metylenu przy zaburzeniach sercowo-naczyniowych
WO2005000403A3 (fr) Compositions et methodes de traitement et de prevention de la degeneration du tissu cardiaque et leurs utilisations
TW200716172A (en) Pharmaceutical compositions for treating lower motor neuron diseases
WO2007022121A3 (fr) Composes o-nitro, compositions pharmaceutiques correspondantes, et leurs utilisations
TW200630083A (en) Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application